280174871 v1 (e) Severability of Provisions. Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision. (f) Counterparts. This Amendment may be executed in any number of counterparts...Loan Agreement • January 26th, 2023 • Myovant Sciences Ltd. • Pharmaceutical preparations
Re: Co-Promotion of MYFEMBREE in Canada Under the Collaboration and License Agreement by and between MYOVANT SCIENCES GMBH (“Myovant”) and PFIZER INC. (“Pfizer”), dated as of December 26, 2020Letter Agreement • January 26th, 2023 • Myovant Sciences Ltd. • Pharmaceutical preparations • New York
This letter agreement (“Letter Agreement”) relates to the Collaboration and License Agreement between Myovant and Pfizer dated as of December 26, 2020 (“Myovant/Pfizer Agreement”), under which Myovant and Pfizer have agreed to co-exclusively co-develop, co-commercialize and co-promote the WH Product(s) and the Oncology Products(s) in the Field in the Co-Promotion Territory (each as defined in the Myovant/Pfizer Agreement), among other activities, in accordance with the terms of the Myovant/Pfizer Agreement.
